Descriptive statistics according to primary disease and GvHD prophylaxis
. | Group A1, n = 47 . | Group A2, n = 26 . | Group FA, n = 37 . |
|---|---|---|---|
| Diseases | AAA TAI | AAA TAI | Fanconi |
| GvHD prophylaxis | CsA | CsA + MTX | CsA |
| Year of transplantation* | 1983/1983/1984 | 1987/1988/1989 | 1984/1989/1992 |
| Range | 1981-1987 | 1986-1990 | 1981-1996 |
| Follow-up time, y* | 11.2/15.1/17.8 | 8.6/12.7/14.9 | 10.6/13.2/15.2 |
| Recipient sex, male, % | 65 (30) | 54 (14) | 62 (23) |
| Recipient age at transplantation, y* | 12/16/22 | 13/26/32 | 7/12/15 |
| Range | 5-46 | 9-46 | 4-26 |
| Diagnosis to BMT, mo* | 2/3/7 | 2/4/12 | 11/22/49 |
| Range | 0-117 | 1-143 | 3-147 |
| Etiology of AAA, % | |||
| Idiopathic | 79 (37) | 54 (14) | — |
| After hepatitis | 13 (06) | 31 (08) | — |
| Others | 8 (04) | 15 (04) | — |
| Treatments before BMT, % | |||
| Androgens | 45 (21) | 27 (07) | 59 (22) |
| ATG | 23 (11) | 31 (08) | 0 (00) |
| At least 20 transfusions | NA | NA | 35 (13) |
| Malformative syndrome, % | |||
| Extensive† | — | — | 27 (10) |
| Kidney + urogenital tract | — | — | 43 (16) |
| Urogenital tract | — | — | 11 (04) |
| Limbs | — | — | 54 (20) |
| Donor sex, male, % | 63 (29) | 54 (14) | 59 (22) |
| Donor/recipient sex match, % | |||
| Female to female | 9 (05) | 27 (07) | 19 (07) |
| Female to male | 28 (13) | 19 (05) | 22 (08) |
| Male to female | 26 (12) | 19 (05) | 19 (07) |
| Male to male | 37 (17) | 35 (09) | 41 (15) |
| Donor/recipient ABO blood groups | |||
| No incompatibility | 79 (37) | 77 (20) | 78 (29) |
| Major incompatibility | 5 (02) | 8 (02) | 11 (04) |
| Recipient CMV serostatus, +, % | 28 (08) | 69 (18) | 52 (14) |
| Nucleated cell dose, 108/kg* | 2.8/3.4/4.8 | 1.9/2.8/3.5 | 2.4/3.6/4.7 |
| Range | 1.0-8.5 | 1.1-5.8 | 0.8-9.8 |
| Neutrophil recovery, d* | 12/16/19 | 14/17/19 | 12/13/18 |
| Range | 8-28 | 8-35 | 10-49 |
. | Group A1, n = 47 . | Group A2, n = 26 . | Group FA, n = 37 . |
|---|---|---|---|
| Diseases | AAA TAI | AAA TAI | Fanconi |
| GvHD prophylaxis | CsA | CsA + MTX | CsA |
| Year of transplantation* | 1983/1983/1984 | 1987/1988/1989 | 1984/1989/1992 |
| Range | 1981-1987 | 1986-1990 | 1981-1996 |
| Follow-up time, y* | 11.2/15.1/17.8 | 8.6/12.7/14.9 | 10.6/13.2/15.2 |
| Recipient sex, male, % | 65 (30) | 54 (14) | 62 (23) |
| Recipient age at transplantation, y* | 12/16/22 | 13/26/32 | 7/12/15 |
| Range | 5-46 | 9-46 | 4-26 |
| Diagnosis to BMT, mo* | 2/3/7 | 2/4/12 | 11/22/49 |
| Range | 0-117 | 1-143 | 3-147 |
| Etiology of AAA, % | |||
| Idiopathic | 79 (37) | 54 (14) | — |
| After hepatitis | 13 (06) | 31 (08) | — |
| Others | 8 (04) | 15 (04) | — |
| Treatments before BMT, % | |||
| Androgens | 45 (21) | 27 (07) | 59 (22) |
| ATG | 23 (11) | 31 (08) | 0 (00) |
| At least 20 transfusions | NA | NA | 35 (13) |
| Malformative syndrome, % | |||
| Extensive† | — | — | 27 (10) |
| Kidney + urogenital tract | — | — | 43 (16) |
| Urogenital tract | — | — | 11 (04) |
| Limbs | — | — | 54 (20) |
| Donor sex, male, % | 63 (29) | 54 (14) | 59 (22) |
| Donor/recipient sex match, % | |||
| Female to female | 9 (05) | 27 (07) | 19 (07) |
| Female to male | 28 (13) | 19 (05) | 22 (08) |
| Male to female | 26 (12) | 19 (05) | 19 (07) |
| Male to male | 37 (17) | 35 (09) | 41 (15) |
| Donor/recipient ABO blood groups | |||
| No incompatibility | 79 (37) | 77 (20) | 78 (29) |
| Major incompatibility | 5 (02) | 8 (02) | 11 (04) |
| Recipient CMV serostatus, +, % | 28 (08) | 69 (18) | 52 (14) |
| Nucleated cell dose, 108/kg* | 2.8/3.4/4.8 | 1.9/2.8/3.5 | 2.4/3.6/4.7 |
| Range | 1.0-8.5 | 1.1-5.8 | 0.8-9.8 |
| Neutrophil recovery, d* | 12/16/19 | 14/17/19 | 12/13/18 |
| Range | 8-28 | 8-35 | 10-49 |
N = 83 for recipient CMV-positive serostatus; N = 103 for neutrophil recovery. N = 110 for all others.
Numbers after percents are frequencies.
AAA indicates acquired aplastic anemia; TAI, thoraco-abdominal irradiation; CsA, cyclosporine A; MTX, methotrexate; N, the number of non-missing values; BMT, bone marrow transplantation; —, not applicable; ATG, antithymocyte globulins; NA, not available; and CMV, cytomegalovirus.
Lower quartile/median/the upper quartile for continuous covariates.
At least 3 anatomic sites involved.24